OnkoSight Advanced^TM for Lung Cancer

OnkoSight Advanced^TM lung cancer panel is optimized to provide high sensitivity and specificity for low-frequency somatic variants. DNA biomarkers include single nucleotide variants (SNVs), insertions, deletions, copy number variants (CNVs), and multinucleotide variants (MNVs).

Many genomic aberrations have been identified that impact therapy selection in non-small cell lung cancer (NSCLC) – a type of lung cancer that accounts for about 80-85% of lung cancer cases. Testing for these aberrations is imperative to:

• Identify an efficacious targeted therapy
• Avoid therapies unlikely to provide clinical benefit

Per the National Comprehensive Cancer Network (NCCN), a broad-based next-generation sequencing (NGS) panel is recommended to identify genomic aberrations in NSCLC. For patients who, in broad panel testing don’t have identifiable driver mutations, an RNA-based NGS may be considered to maximize the detection of fusion events.

GenPath® Oncology, a division of BioReference®, prides itself on being a leading provider of cutting-edge cancer diagnostics with industry-leading turnaround times. GenPath offers comprehensive profiles for lung cancer, that includes DNA, RNA, and PD-L1 22C3 (Test code M338-2), as well as targeted DNA and RNA panels and other tests for lung cancer to assist healthcare providers in identifying targeted treatment strategies.

Test Information